Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Taiko Pharmaceutical Co.,Ltd. (4574.T)
Osaka, JP
Taiko Pharmaceutical Co.,Ltd. operates primarily in the pharmaceutical sector and the field of infection prevention. The company manufactures and distributes various over-the-counter medications, including its well-known Seirogan and Seirogan Toi-A brands, which are formulated to alleviate symptoms such as loose stools, diarrhea, vomiting, and ailments stemming from food or water contamination. Additionally, it provides specific tablets for diarrhea relief and quasi-pharmaceuticals like the Trumpet Intestinal Regulator BF. In its infection control segment, Taiko Pharmaceutical produces and supplies a range of sanitation products under the Cleverin brand to wholesalers. This includes the Cleverin generator, a device engineered to emit low concentrations of chlorine dioxide gas. The company also leverages its proprietary Cleverin technology by supplying it through original equipment manufacturer (OEM) agreements and engaging in joint product development ventures with other businesses. Its products are exported to several countries, including the United States, Canada, Thailand, Vietnam, Malaysia, and Mongolia. Taiko Pharmaceutical Co.,Ltd. was founded in 1946 and is headquartered in Osaka, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.80% | -11.03% | -13.71% | -17.57% | -11.03% | -14.29% | -2.64% | -34.35% | -76.69% | -46.51% | -7.86% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+1.7% Q1'26: -20.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+2.7% Q1'26: -132.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+8.0% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.2% Q1'26: -10.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.7% ★ Q1'26: -7.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.1% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.13× ★ Q1'26: -4.99× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.87B
est: 8.90B (+10.9%)
|
9.24B
est: 8.15B (+13.3%)
|
8.30B
est: 8.20B (+1.2%)
|
8.28B
est: 9.10B (-9.0%)
|
9.44B
est: 9.80B (-3.7%)
|
10.38B
est: 16.20B (-35.9%)
|
14.94B
est: 18.75B (-20.3%)
|
17.68B
est: 18.75B (-5.7%)
|
10.72B
est: 11.70B (-8.4%)
|
5.04B
est: 8.30B (-39.3%)
|
6.12B
est: 10.50B (-41.7%)
|
6.29B
est: 6.55B (-3.9%)
|
6.40B
est: 6.10B (+4.9%)
|
6.75B
6.75B – 6.75B
+10.7% YoY
|
7.52B
7.52B – 7.52B
+11.4% YoY
|
8.30B
8.30B – 8.30B
+10.4% YoY
|
| EBITDA |
2.98B
est: -2.23B (+233.5%)
|
2.86B
est: -2.04B (+239.8%)
|
1.66B
est: -2.06B (+180.7%)
|
1.91B
est: -2.28B (+183.5%)
|
2.33B
est: -2.46B (+194.6%)
|
2.39B
est: -4.06B (+158.8%)
|
4.07B
est: -4.70B (+186.5%)
|
5.92B
est: -4.70B (+225.9%)
|
-5.57B
est: -2.93B (-89.7%)
|
-3.75B
est: -2.08B (-80.1%)
|
-2.85B
est: -2.63B (-8.2%)
|
882.00M
est: -1.93B (+145.6%)
|
724.00M
est: -1.80B (+140.2%)
|
-1.99B
-1.99B – -1.99B
-10.7% YoY
|
-2.22B
-2.22B – -2.22B
-11.4% YoY
|
-2.45B
-2.45B – -2.45B
-10.4% YoY
|
| EBIT |
—
est: -2.20B (+100.0%)
|
2.56B
est: -2.01B (+227.2%)
|
—
est: -2.02B (+100.0%)
|
—
est: -2.25B (+100.0%)
|
1.86B
est: -2.42B (+176.8%)
|
—
est: -4.00B (+100.0%)
|
—
est: -4.63B (+100.0%)
|
5.65B
est: -4.63B (+222.1%)
|
-4.95B
est: -2.89B (-71.3%)
|
-3.08B
est: -2.05B (-50.3%)
|
-3.56B
est: -2.59B (-37.1%)
|
626.00M
est: -1.94B (+132.2%)
|
459.00M
est: -1.81B (+125.4%)
|
-2.00B
-2.00B – -2.00B
-10.7% YoY
|
-2.23B
-2.23B – -2.23B
-11.4% YoY
|
-2.46B
-2.46B – -2.46B
-10.4% YoY
|
| Net Income |
1.75B
est: 1.97B (-11.4%)
|
1.77B
est: 1.29B (+37.1%)
|
840.11M
est: 1.44B (-41.5%)
|
1.05B
est: 1.30B (-19.4%)
|
1.09B
est: 1.34B (-18.4%)
|
1.42B
est: 3.66B (-61.3%)
|
2.45B
est: 4.83B (-49.2%)
|
3.85B
est: 4.83B (-20.2%)
|
-9.59B
est: -3.80B (-152.5%)
|
-4.89B
est: -1.61B (-203.8%)
|
-3.61B
est: 230.84M (-1,664.3%)
|
898.00M
est: 622.94M (+44.2%)
|
923.00M
est: 579.73M (+59.2%)
|
648.05M
648.05M – 648.05M
+11.8% YoY
|
999.71M
999.71M – 999.71M
+54.3% YoY
|
1.10B
1.10B – 1.10B
+10.1% YoY
|
| SGA |
—
est: 1.85B (-100.0%)
|
—
est: 1.69B (-100.0%)
|
—
est: 1.70B (-100.0%)
|
—
est: 1.89B (-100.0%)
|
4.70B
est: 2.04B (+130.6%)
|
5.13B
est: 3.37B (+52.4%)
|
—
est: 3.90B (-100.0%)
|
—
est: 3.90B (-100.0%)
|
—
est: 2.43B (-100.0%)
|
—
est: 1.72B (-100.0%)
|
3.58B
est: 2.18B (+64.2%)
|
2.85B
est: 1.98B (+44.1%)
|
3.02B
est: 1.84B (+63.9%)
|
2.04B
2.04B – 2.04B
+10.7% YoY
|
2.27B
2.27B – 2.27B
+11.4% YoY
|
2.51B
2.51B – 2.51B
+10.4% YoY
|
| EPS |
45.31
est: 39.30 (+15.3%)
|
46.31
est: 25.73 (+80.0%)
|
21.74
est: 28.63 (-24.1%)
|
25.48
est: 25.93 (-1.7%)
|
25.80
est: 26.73 (-3.5%)
|
33.00
est: 72.90 (-54.7%)
|
57.57
est: 96.20 (-40.2%)
|
89.18
est: 96.20 (-7.3%)
|
-220.48
est: -75.70 (-191.3%)
|
-112.24
est: -32.10 (-249.7%)
|
-76.25
est: 4.60 (-1,757.6%)
|
17.89
est: 12.40 (+44.3%)
|
18.37
est: 11.54 (+59.2%)
|
12.90
12.90 – 12.90
+11.8% YoY
|
19.90
19.90 – 19.90
+54.3% YoY
|
21.90
21.90 – 21.90
+10.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Core TOPIX ETF 1475.T | 0.00% | 153.8K | 0.05% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Takashi Shibata | President, Chief Executive Officer & Representative Director | 116M | male |
| Konosuke Tanaka | Executive Officer of Personnel Affairs & Public Relations | — | — |
| Masaji Hashimoto | Senior Managing Director & Director | — | male |
| Mitsuhiro Yamashita | Executive Officer of Overseas Business | — | — |
| Shinichi Seki | Executive Officer & GM of Infection Control Business Development Division | — | — |
| Takatoshi Osada | Senior Executive Officer of Marketing & Sales | — | — |
| Keizo Nakada | Executive Officer | — | — |
| Tsuyoshi Honma | Executive Officer of Accounting & IT | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4574.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
